复朗基因
FLGT
19.81
-1.53
-7.17%
复朗基因
US · FLGT
#3667 按市值排名
上市于 2016
19.81
-1.53
-7.17%
实时 - 追踪5344个代码 - 心跳于496秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 57.77% -0.03pp
- 机构数量
- 180
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund39.97%
Individual/Insider39.34%
Hedge Fund10.40%
Public Company4.88%
Private Company1.25%
Family Office/Trust0.87%
Government Pension Fund0.25%
Insurance Company0.15%
Other2.89%
主要股东 截至 2026-09-01
Ming Hsieh
32.25% · 8.87M 股
BlackRock
8.31% · 2.29M 股
Acadian Asset Management LLC
3.70% · 1.02M 股
Hanlin Gao
3.58% · 986.12K 股
Vanguard Capital Management, LLC
3.33% · 915.91K 股
Jacobs Levy Equity Management Inc
2.84% · 782.12K 股
JPMorgan Chase & Co.
2.61% · 717.22K 股
Diametric Capital, LP
2.54% · 697.78K 股
Columbia Management Investment Advisers, LLC
2.44% · 670.08K 股
Dimensional Fund Advisors
2.27% · 625.36K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 12次买入 · 38次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Ming Hsieh | Chairperson & CEO | 32.25% |
| Hanlin Gao | Chief Scientific Officer & Laboratory Director | 3.58% |
| Jian Xie | Chief Operating Officer | 2.11% |
| Paul Kim | Chief Financial Officer | 1.30% |
| Linda Dong | Independent Director | 0.04% |
| Michael Nohaile | Independent Director | 0.03% |
| Regina Groves | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-01 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -1,673 | $19.66 |
| 2026-09-01 | Jian Xie | Chief Operating Officer | Open Market Disposition | -2,127 | $19.66 |
| 2026-08-31 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,087 | $19.59 |
| 2026-08-31 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -4,392 | $19.59 |
| 2026-08-26 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -939 | $19.91 |
| 2026-08-26 | Jian Xie | Chief Operating Officer | Open Market Disposition | -1,193 | $19.91 |
| 2026-08-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -1,168 | $19.81 |
| 2026-08-25 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -2,949 | $19.81 |
| 2026-07-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,747 | $19.67 |
| 2026-07-25 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Sale to Issuer | -1,645 | $19.67 |
| 2026-07-25 | Jian Xie | Chief Operating Officer | Sale to Issuer | -4,361 | $19.67 |
| 2026-06-01 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -1,688 | $17.89 |
| 2026-06-01 | Jian Xie | Chief Operating Officer | Open Market Disposition | -2,146 | $17.89 |
| 2026-05-31 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,087 | $18.09 |
| 2026-05-31 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -4,392 | $18.09 |
| 2026-05-26 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -945 | $17.60 |
| 2026-05-26 | Jian Xie | Chief Operating Officer | Open Market Disposition | -1,201 | $17.60 |
| 2026-05-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -1,168 | $17.67 |
| 2026-05-25 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -2,949 | $17.67 |
| 2026-05-13 | Regina Groves | Independent Director | Other Acquisition | +11,117 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
复朗基因 讨论区 0 条评论